There are several legislative proposals in Congress, some stalled and some nascent, that would propose a $35 per-month cap on what insured Americans would pay out-of-pocket for insulin – and this cap in costs would benefit about 25% of those on individual and small group markets, and about 20% of those in larger employer-sponsored plans.